These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 38456597)

  • 21. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.
    Manolopoulos VG; Ragia G; Tavridou A
    Pharmacogenomics; 2011 Aug; 12(8):1161-91. PubMed ID: 21843065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of poor glycemic control among type 2 diabetes mellitus patients treated with antidiabetic medications: A cross-sectional study in China.
    Wang J; Li J; Wen C; Liu Y; Ma H
    Medicine (Baltimore); 2021 Oct; 100(43):e27677. PubMed ID: 34713865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to anti-diabetic drugs among patients with Type 2 diabetes mellitus at Muhimbili National Hospital, Dar es Salaam, Tanzania- A cross-sectional study.
    Rwegerera GM
    Pan Afr Med J; 2014; 17():252. PubMed ID: 25309652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis.
    Tan L; Wang Z; Okoth K; Toulis KA; Denniston AK; Singh BM; Crowe FL; Sainsbury C; Wang J; Nirantharakumar K
    Front Endocrinol (Lausanne); 2023; 14():1303238. PubMed ID: 38239984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidiabetic Treatment, Level of Glycemic Control, and Risk of Fracture in Type 2 Diabetes: a Nested, Case-Control Study.
    Charlier S; Vavanikunnel J; Becker C; Jick SS; Meier C; Meier CR
    J Clin Endocrinol Metab; 2021 Jan; 106(2):554-566. PubMed ID: 33141149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
    Feng YH; Velazquez-Torres G; Gully C; Chen J; Lee MH; Yeung SC
    J Cell Mol Med; 2011 Apr; 15(4):825-36. PubMed ID: 20455996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
    Fioretto P; Giaccari A; Sesti G
    Cardiovasc Diabetol; 2015 Oct; 14():142. PubMed ID: 26474563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive and negative effects of glitazones in carcinogenesis: experimental models vs. clinical practice.
    Bojková B; Orendáš P; Kubatka P; Péč M; Kassayová M; Kisková T; Kajo K
    Pathol Res Pract; 2014 Aug; 210(8):465-72. PubMed ID: 25023882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of diabetes: Crossing to the other side.
    Skliros NP; Vlachopoulos C; Tousoulis D
    Hellenic J Cardiol; 2016; 57(5):304-310. PubMed ID: 27687958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin therapy for maximal glycemic control in type 2 diabetes mellitus.
    Spellman CW
    J Am Osteopath Assoc; 2007 Jul; 107(7):260-9. PubMed ID: 17682113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of diabetes: a clinical update on insulin trials.
    LeRoith D
    Clin Cornerstone; 2007; 8(2):21-9; discussion 30-2. PubMed ID: 18357953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
    Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of potential drug-drug interactions with antidiabetic drugs.
    Samardzic I; Bacic-Vrca V
    Pharmazie; 2015 Jun; 70(6):410-5. PubMed ID: 26189304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
    Cooke CE; Lee HY; Tong YP; Haines ST
    Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease.
    Zhang F; Ji L; Hong T; Guo L; Li Y; Zhu Z; Liu X; Liu F; Tang L; Zhang Y; Li J; Lü Q; Tong N
    J Evid Based Med; 2022 Jun; 15(2):168-179. PubMed ID: 35715995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antidiabetic effect of total flavonoids from Sanguis draxonis in type 2 diabetic rats.
    Chen F; Xiong H; Wang J; Ding X; Shu G; Mei Z
    J Ethnopharmacol; 2013 Oct; 149(3):729-36. PubMed ID: 23933499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
    Grunberger G
    Curr Diab Rep; 2017 Apr; 17(4):21. PubMed ID: 28293908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus.
    Liu W; Luo Z; Zhou J; Sun B
    Front Cell Infect Microbiol; 2022; 12():853771. PubMed ID: 35711668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.
    Lin E; Garmo H; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
    BMC Cancer; 2020 Jun; 20(1):551. PubMed ID: 32539807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics of oral antidiabetic therapy.
    Ordelheide AM; Hrabě de Angelis M; Häring HU; Staiger H
    Pharmacogenomics; 2018 Apr; 19(6):577-587. PubMed ID: 29580198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.